Design and manufacture of high-throughput microfluidics for cell culture

用于细胞培养的高通量微流体的设计和制造

• 批准号: 69607
• 金额: $ 44.6万
• 依托单位: MICROFLUIDX LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=69607
• 关键词: Design; manufacture; throughput; microfluidics; cell

Public descriptionMicrofluidX's mission is to tackle the problems of process control, scalability, and cost associated with cell bioprocessing, in particular for autologous cell therapy (CT). Its automated, closed technology allows biologists to easily carry out process development by running dozens of cell culture conditions in parallel with extreme process control, and to scale up seamlessly up to several billion cells for manufacturing at a fraction of the current costs. This project is to develop a large-scale microfluidic platform, compatible with a variety of cell research and cell production microfluidic chips, to address the need of high-throughput cell culture in manufacturing and research fields. Microfluidic cell culture has been proven to be superior to conventional cell culture tools with respect to process control and efficiency. So far, these advantages have been exploited successfully for applications requiring small amounts of cells, e.g., cell-based drug screening. By developing a high-throughput platform, MicrofluidX brings microfluidic cell culture to a broad range of new applications in CT and cell-based assays.

MicrofluidX的使命是解决与细胞生物处理相关的过程控制，可扩展性和成本问题，特别是自体细胞治疗（CT）。其自动化的封闭技术使生物学家能够通过运行数十种细胞培养条件与极端过程控制并行轻松进行过程开发，并以当前成本的一小部分无缝扩展到数十亿个细胞。本项目旨在开发一种大规模的微流控平台，兼容多种细胞研究和细胞生产的微流控芯片，以满足制造和研究领域高通量细胞培养的需要。微流体细胞培养已被证明在过程控制和效率方面上级常规细胞培养工具。到目前为止，这些优点已经成功地用于需要少量细胞的应用，例如，细胞药物筛选通过开发高通量平台，MicrofluidX将微流控细胞培养带入了CT和基于细胞的分析中的广泛新应用。